Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT6021 Monotherapy or w/ Tislelizumab in Advanced Solid Tumors
NCT05120375Phase 1Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Feb 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT6021 in solid tumor (advanced stage) (8 cohorts), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 3 weeks and Maximum Tolerated Dose at 3 weeks. Started Feb 2022; status: terminated.
02
Drugs
BAT6021
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05120375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05120375.